Lithium for mild-to-moderate Alzheimer's disease: A randomized double-blind, placebo-controlled study

Lithium for mild-to-moderate Alzheimer's disease: A randomized double-blind, placebo-controlled study - Lithium for mild-to-moderate Alzheimer's disease: A randomized double-blind, placebo-controlled study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020128

Enrollment

100

Registered

2015-12-11

Start date

2016-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

Lithium, 300 micrograms/day, once daily, 52 weeks Placebo, once daily, 52 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients has probable Alzheimer's disease that met Diagnostic and Statistical Manual of Mental Disorders-V criteria. Clinical Dementia Rating scores: 1 or 2

Exclusion criteria

Exclusion criteria: Creatinine clearance < 30

Design outcomes

Primary

Measure	Time frame
A change total score of Alzheimer's disease assessment scale-cognitive subscale from baseline to endpoint.	—

Countries

Japan

Contacts

Public ContactShinji Matsunaga

Fujita Health University School of Medicine Department of Geriatrics and Cognitive Disorders

shinjim@fujita-hu.ac.jp0562-93-9250

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Lithium for mild-to-moderate Alzheimer&#39;s disease: A randomized double-blind, placebo-controlled study